FDA cancer guy says "no more me-too drugs" -- focus on the cutting edge instead.

Guess what CTIX is doing?

Quote:

---

Stay focused on the cutting edge, and lose the me-too drugs in the cancer pipeline.

"People should ask themselves ... would we be better off spending those resources into looking at more novel drugs ?" Pazdur told Reuters at ASCO. Going after the same objectives with very similar therapies is all “about reduction of risk,” he added.

---

http://www.fiercebiotech.com/fda-s-pazdur-chi...e=internal